Pharmaceutical Digital Transformation in Practice: AUTOMA+ 2026

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2026 takes place in Zurich on 16-17 November and reflects companies' approach to digital transformation as a business and operational priority. The Congress addresses major industry developments, including automation, AI adoption, integrated digital ecosystems and patient-focused innovation, through real implementation experience and cross-industry collaboration.

AUTOMA+ has a closed-door format designed to support business decision-making by connecting pharmaceutical companies with technology partners, implementation and operational expertise across automation and digitalisation projects.

“Open discussion of customer challenges creates space for honest dialogue” - Securikett.

This environment encourages transparent exchange around operational barriers, solution strategies and long-term cooperation opportunities.

“AUTOMA+ provides confidence in identifying relevant service providers and highlights the importance of direct interaction with software developers working across multiple technology domains” - RidNova Pharmaceuticals.

Bridging gaps between IT, quality, manufacturing and business teams remains a central objective of the Congress. Participation from pharmaceutical manufacturers, engineering companies, startups and international health organisations reflects the multidisciplinary nature of pharmaceutical digitalisation.

“AUTOMA+ is a strategic reference point for understanding automation trends and evaluating organisational digital maturity” - Jacobs Engineering.

In 2026, AUTOMA+ provides a comprehensive view of digital transformation across R&D, manufacturing, packaging and supply chain operations. The agenda highlights how integrated digital ecosystems support faster drug development, more resilient manufacturing and greater supply chain transparency.

A strong emphasis is placed on AI and data-driven innovation, covering:

laboratory automation;
digital factory models;
advanced analytics;
real-world evidence in drug development and lifecycle management;
cross-functional collaboration and aligning digital initiatives.

AUTOMA+ 2026 further explores the expanding role of digital health and patient-centric engagement strategies, such as personalised patient interaction, connected health solutions and data-driven commercial models, treatment outcomes and healthcare collaboration.
With its focus on applied use cases, regulatory realities and cross-functional alignment, AUTOMA+ 2026 positions digitalisation as a business and quality-driven transformation rather than a purely technical exercise.

See why industry leaders return - explore real feedback and insights at AUTOMA+ 2026

Source: BGS Group

23.02.2026